FDA Starts Push for Transparency in Fulfilling Their 2018 Compounding Policy Priorities Plan (Part II)
Just days after FDA Commissioner Dr. Scott Gottlieb shared the 2018 Compounding Policy Priorities Plan, FDA issued three guidances: (1) Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act ; (2) Compounded Drug Products That Are Essentially Copies of Approved Drug […]